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Introduction
Blau syndrome is an autosomal dominant monogenic
granulomatous disease associated with gain of function
mutations at or near the NACHT domain of NOD2; it is
the only form of granulomatous arthritis with a known
gene mutation. Although its phenotype has been amply
described as a triad of arthritis, uveitis and dermatitis in
case series and retrospective cohorts, prospective studies
on natural history and outcome have not been done.
Objectives
To prospectively study in detail the phenotypic charac-
teristics, functional articular and visual outcomes and
radiographic progression of joint disease in patients with
BS. Secondary goals are to investigate biomarkers of dis-
ease activity as well as to explore relevant pathogenic
pathways and candidates for therapeutic targeting.
Methods
Participating centers of an international registry were
invited to enroll patients with documented NOD2 muta-
tion after IRB approval. This 3 year prospective study
consists of one baseline and 3 yearly visits comprising a
comprehensive clinical evaluation, functional assessment
(CHAQ/HAQ), visual analogue scales, full ophthalmolo-
gic assessment and wrists/hand radiographs at baseline
and at last evaluation. Poznansky and Sharp scores were
utilized to analyze pediatric and adult X-rays respec-
tively. Blood sampling was performed for follow up and
exploratory for biomarkers. Drug therapy was recorded.
Coded data were kept in a secured database at the coor-
dinating center.
Results
We are reporting here baseline articular and functional
data of the first 25 recruited patients. F: 8; M: 17.
Ages:0-54 years;50% 0-15. More than half carried substi-
tution R334W or R334Q. Onset of joint disease was 33
months (3-156). At evaluation arthritis duration was
15.7 yrs (1-53). Mean active joint count was 7 (0-24).
Mean CHAQ/HAQ 0.42 (0-2). VAS-p 1.78 (0-8) and
VAS-g 2.06 (0-8). A subgroup of patients with long
duration (20-50 years) showed a mean joint count of
11.4 (1-24), HAQ of 0.9 (0-2), VAS-p of 4.9 (0-8), VAS-
g of 4.1 (0-8). 11/25 required daily systemic prednisone
with methotrexate and/or biologics. Significant destruc-
tive radiographic changes were documented over time.
50% of the entire group showed extra-triad manifesta-
tions with lymphadenopathy, fever, erythema nodosum
and hypertension the most common.
Conclusion
This first prospective study on the natural history of BS
demonstrates a relentlessly active and destructive articu-
lar involvement with significant functional morbidity,
exhibiting high levels of disability and disease activity
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